Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases

• Published in: Neuro-oncology advances 2020-01, Vol.2 (1), p.vdaa038-vdaa038
• Main Authors: Berghoff, Anna Sophie, Breckwoldt, Michael Oliver, Riedemann, Lars, Karimian-Jazi, Kianush, Loew, Sarah, Schlieter, Franziska, Furtner, Julia, Cinci, Marc, Thomas, Michael, Strowitzki, Moritz J, Marmé, Frederik, Michel, Laura L, Schmidt, Thomas, Jäger, Dirk, Bendszus, Martin, Preusser, Matthias, Wick, Wolfgang, Winkler, Frank
• Format: Article
• Language: English
• Subjects: Clinical Investigations
• ISSN: 2632-2498; 2632-2498
• DOI: 10.1093/noajnl/vdaa038

Abstract Background Salvage treatment for recurrent brain metastases (BM) of solid cancers is challenging due to the high symptomatic burden and the limited local treatment options. Methods Patients with recurrent BM with no option for further local therapies were retrospectively identified from BM databases. Bevacizumab-based treatment was initiated as a salvage treatment. Radiological imaging before and after bevacizumab-based treatment was reevaluated for treatment response using the Response Assessment in Neuro-Oncology (RANO) BM criteria. Results Twenty-two patients (36.4% male) with recurrent BM from breast cancer (40.9%), colorectal cancer (31.8%), or lung cancer (27.3%) were identified. Previous BM-directed therapies were radiosurgery in 16/22 (72.7%) patients, whole-brain radiotherapy in 8/22 (36.4%), and neurosurgical resection in 11/22 (50.0%). Time since BM diagnosis to initiation of bevacizumab treatment was 16.5 months. Of 22 patients 14 (63.6%) received concurrent systemic therapies. Neurological symptom improvement could be achieved in 14/22 (63.6%) and stabilization in 6/22 (27.3%) patients, resulting in a clinical benefit in 20/22 (90.9%) patients. Steroids could be reduced or stopped in 15/22 (68.2%) patients. Rate of improvement on T1-weighted imaging was 15/19 (78.9%; median reduction: −26.0% ± 32.9) and 19/20 (95%; median reduction: −36.2% ± 22.2) on T2-weighted FLAIR imaging. According to RANO-BM best response was partial response in 7/19 (36.8%), stable disease in 9/19 (47.3%), and progressive disease in 3/19 (15.7%) patients. Median CNS-specific progression-free survival was 8 months and median overall survival after initiation of bevacizumab treatment was 17 months. Conclusions Bevacizumab-based treatment had clinically relevant intracranial activity in the vast majority of patients suffering from recurrent, symptomatic BM. The data supports a prospective clinical trial of bevacizumab as a salvage treatment in BM.